값202020212022202320242025TTM투자 활동으로 인한 현금-435.52 M-273.3 M169.35 M-336.35 M-116.84 M436.33 M348.1 M재무활동으로 인한 현금994.98 M1.25 B425.75 M172.13 M294.16 M-305.19 M-333.56 M잉여 현금 흐름-614.96 M-641.69 M-541.27 M104.16 M-8.31 M465.38 M641.34 M
Alnylam Pharmaceuticals, Inc. - Common Stock
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.